CJC 1295 NO DAC

Both are the same modified 29-amino-acid fragment of growth-hormone-releasing hormone, GHRH(1-29), with four amino-acid substitutions that resist enzymatic breakdown. CJC-1295 DAC adds a Drug Affinity Complex (a maleimidopropionyl linker on the C-terminal lysine) that bonds to albumin, giving it a much longer half-life in research models. The no-DAC version, also called modified GRF(1-29), lacks the linker and is cleared quickly.

No. HGH is the 191-amino-acid growth hormone itself. Ipamorelin, GHRP-6, hexarelin, sermorelin, CJC-1295 and tesamorelin are much smaller synthetic peptides, called growth hormone secretagogues, that act on pituitary receptors controlling the body's own release of growth hormone: the ghrelin receptor (GHS-R1a) or the GHRH receptor. None of them contains the growth hormone sequence.

Both are synthetic GHRH analogues that act on the GHRH receptor, stabilized against enzymatic breakdown in different ways. Tesamorelin is the full 44-amino-acid GHRH sequence with a trans-3-hexenoyl group on the N-terminus. CJC-1295 is the shorter 29-residue fragment with four amino-acid substitutions; the DAC version adds a linker that bonds to albumin. Tesamorelin is an FDA-approved active ingredient; CJC-1295 has never been approved.

Closely related but not the same. CJC-1295 without DAC (modified GRF 1-29) is the sermorelin sequence, GHRH(1-29), with four amino-acid substitutions: D-alanine at position 2, glutamine at 8, alanine at 15 and leucine at 27. These make it more resistant to enzymatic breakdown. CJC-1295 DAC adds a lysine and a maleimidopropionyl linker that bonds to albumin. All three act on the GHRH receptor.

Sermorelin, CJC-1295 and tesamorelin are all GHRH analogues acting on the GHRH receptor: sermorelin is the native 29-amino-acid fragment, CJC-1295 (no DAC) is that fragment with four stabilizing substitutions, and tesamorelin is the full 44-residue sequence with an N-terminal hexenoyl group. The CJC-1295/ipamorelin blend adds a second compound, ipamorelin, which acts on a different receptor, the ghrelin receptor (GHS-R1a).

No. Neither CJC-1295 DAC nor CJC-1295 without DAC (modified GRF 1-29) has been approved by the FDA or any other major regulator. CJC-1295 DAC reached early-phase clinical studies before its developer discontinued it. Both are research compounds, sold here for laboratory research use only.

No. CJC-1295 is a 29-residue GHRH analogue that acts on the GHRH receptor; the DAC version adds an albumin-binding linker. Ipamorelin is a 5-amino-acid peptide that acts on a different receptor, the ghrelin receptor (GHS-R1a). The two are unrelated in sequence, which is why they are often supplied together: they act on the two separate receptor pathways that regulate pituitary growth hormone release.

MK-677 (ibutamoren) is not a peptide: it is a small-molecule ghrelin-receptor agonist developed by Merck in the 1990s. Ipamorelin and GHRP-6 are peptides that act on that same ghrelin receptor (GHS-R1a), while CJC-1295 acts on a different one, the GHRH receptor. None of these is FDA approved. We do not sell MK-677.

These belong to unrelated research areas. BPC-157 (a 15-amino-acid gastric-protein-derived peptide) and TB-500 (derived from the actin-binding protein thymosin β4) are studied in tissue-repair models. CJC-1295, sermorelin and tesamorelin are GHRH analogues acting on the GHRH receptor in the growth hormone axis. They share no sequence, receptor or pathway.

In the United States, CJC-1295 is not a controlled substance and can be lawfully purchased as a research chemical for laboratory use. It is not an approved drug, so selling it for human use or with health claims is unlawful. The World Anti-Doping Agency names CJC-1295 among the GHRH analogues in class S2, prohibited in sport at all times. This is general information, not legal advice.

CJC-1295 no DAC, also called modified GRF(1-29) or mod GRF, is a synthetic 29-amino-acid analogue of growth-hormone-releasing hormone. It is the sermorelin sequence with four substitutions (D-Ala2, Gln8, Ala15, Leu27) that resist enzymatic breakdown. Unlike CJC-1295 DAC, it has no albumin-binding linker. It acts on the GHRH receptor and is not FDA approved.

Published research specifically on modified GRF(1-29) is limited. Most of the relevant literature concerns GHRH(1-29) analogues in general: the work in the 1980s and 1990s that identified substitutions at positions 2, 8, 15 and 27 as protecting the peptide from enzymatic breakdown, and studies of GHRH receptor signaling in pituitary cell and rodent models. It has not been through formal clinical development. Findings in cells or animals do not establish effects in people.

Because they act on complementary receptor targets. Pituitary growth hormone release is regulated by two separate receptor pathways: the GHRH receptor, targeted by CJC-1295, and the ghrelin receptor (GHS-R1a), targeted by ipamorelin. Researchers studying how the two pathways interact often use one compound from each class, so a co-lyophilized vial offers both in a fixed ratio. A blend is a convenience format, not an approved product.

The blend fixes a 1:1 mass ratio (5 mg + 5 mg) in one vial, which saves a reconstitution step and keeps the ratio identical across experiments. Separate vials let a researcher vary each peptide independently, run single-compound controls, and switch between CJC-1295 with or without DAC. Choose separate vials when the experiment needs either compound on its own.

They act on different receptors. GHRP-6, GHRP-2 and hexarelin are small synthetic hexapeptides that act on the ghrelin receptor (GHS-R1a). CJC-1295, sermorelin and tesamorelin are much longer analogues of growth-hormone-releasing hormone, 29 to 44 amino acids, that act on the GHRH receptor. Both receptors are on pituitary cells and regulate growth hormone release through separate signaling pathways.

They sit at different points of the growth hormone axis. CJC-1295, sermorelin and tesamorelin (GHRH receptor) and ipamorelin, GHRP-6 and hexarelin (ghrelin receptor) are small peptides that act on pituitary receptors controlling growth hormone release. IGF-1 LR3 acts further downstream: it is an analogue of IGF-1, the hormone produced largely in response to growth hormone, and binds the IGF-1 receptor directly.

They are not in the same pathway. Follistatin is a binding protein that captures activin, myostatin and related TGF-β family ligands outside cells. IGF-1 LR3 acts on the IGF-1 receptor, and CJC-1295 and tesamorelin act on the GHRH receptor in the growth hormone axis. Follistatin is a large recombinant glycoprotein; CJC-1295 and tesamorelin are synthetic peptides.

CJC 1295 NO DAC: molecular formula C152H252N44O42; molecular weight 3367.9 g/mol. Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2. Match these identifiers against the Certificate of Analysis for the lot.

Yes. Each lot has its own Certificate of Analysis, linked on this page for the current lot of each size: 5mg (99.85% HPLC purity); 10mg (99.6% HPLC purity). Past certificates are archived in the COA library; contact us with the lot number on the vial label if a certificate is missing.

99.6% (HPLC, current lot). Purity is measured by high-performance liquid chromatography (HPLC) and reported on the lot's Certificate of Analysis.

CJC 1295 NO DAC is supplied as lyophilized powder in a sealed vial in 2 sizes: 5mg, 10mg. In stock and dispatched in 1–2 business days. Quantity pricing applies automatically at 5+ and 10+ vials of the same size.

Store sealed at −20 °C, dry and protected from light.